The ABPI in Scotland has appointed Sandra Auld as its new director after the previous post holder Andrew-Powrie Smith recently left to work at the EFPIA pharma trade group.
Auld will be responsible for helping to address the health needs of Scottish patients and representing the interests of the pharmaceutical industry in Scotland.
She will spearhead the ABPI Scotland team, working closely with the Scottish Government and NHS Scotland.
Auld has a diverse background with NHS, university and private sector experience and joined the ABPI as operations director in May 2010.
Previously, she worked for the NHS Scottish Centre for Telehealth – prior to this, Sandra spent 10 years heading a nurse research team with the Department of Public Health Sciences at the University of Edinburgh.
She later joined Solvay Healthcare, then Boehringer Ingelheim as health policy manager.
Alison Clough, the ABPI’s acting CEO, said: “I am delighted to appoint Sandra as our Director of ABPI Scotland. Sandra’s range of knowledge and experience will be hugely beneficial in working closely with members, partners and stakeholders across the life sciences environment in Scotland and in helping to improve the access to and use of new and innovative medicines for Scottish patients.
“In addition, Sandra will continue to lead all initiatives to improve the environment for the pharmaceutical industry in Scotland and its role in contributing to the UK economy.”
Auld added: “I am absolutely delighted to become the Director of ABPI Scotland. The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing value of new and innovative medicines.”